BDTXBlack Diamond Therapeutics
About Black Diamond Therapeutics
Black Diamond Therapeutics (NASDAQ:BDTX) is a biotechnology firm dedicated to discovering and developing precision medicines for cancer patients. With a focus on addressing genetically defined diseases driven by oncogenes, the company leverages its proprietary technology platform to target and inhibit elusive cancer-driving proteins. Black Diamond Therapeutics aims to unveil new treatment options for patients with limited or no existing therapeutic avenues, emphasizing a commitment to innovation and patient care in the oncology sector.
What is BDTX known for?
Snapshot
Public US
Ownership
2014
Year founded
54
Employees
Cambridge, United States
Head office
Loading Map...
Operations
All Locations
Newton, US
Products and/or services of Black Diamond Therapeutics
- Development of BDTX-1535, a targeted therapy for lung and brain cancers with specific genetic mutations.
- Creation of a platform for discovering MasterKey therapies for genetically defined cancers.
- Research on a new class of small molecule therapies designed to target allosteric mutations across multiple cancer types.
- Development of diagnostic tools to identify patients who could benefit from their MasterKey therapies.
Black Diamond Therapeutics executive team
- Dr. Mark A. Velleca M.D., Ph.D.CEO, President & Chairman
- Mr. Brent Hatzis-Schoch Esq., J.D.COO & General Counsel
- Dr. Sergey Yurasov M.D., Ph.D.Chief Medical Officer
- Dr. Elizabeth Buck Ph.D.Co-Founder & Chief Scientific Officer
- Ms. Erika JonesPrincipal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
- Ms. Melanie MorrisonChief Development Officer